YD Bio, EG BioMed Launch AI Cancer Risk Assessment

MT newswire2026/10/06 13:07

09:07 AM EDT, 10/06/2026 (MT Newswires) -- YD Bio (YDES) said Tuesday it launched along with EG BioMed an AI-powered cancer risk assessment that organizes self-reported health information into personalized reports covering 10 cancer types. The 52-question assessment takes about 10 minutes and provides low, moderate or high risk stratification based on a 48-feature pan-cancer model and 10 cancer-specific models, YD Bio said. The service is available in English and Chinese for a promotional price of $10, reduced from $50, the company said. YD Bio said the tool does not diagnose cancer or replace medical evaluation. Shares of YD Bio were down 7.7% in premarket activity Tuesday.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.